The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Kids V Cancer named one of top 10 most innovative companies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

KIDS V CANCER was named as one of Fast Company’s Top 10 Most Innovative Companies of 2016 in Not-For-Profit, placing fourth. Fast Company praised Kids v Cancer for accelerating the discovery of pediatric cancer treatments.

Other organizations in this category include Black Lives Matter, 92nd St Y, Humans Of New York and UNICEF. Last year, Kids v Cancer received the 2015 Peter F. Drucker Award for Nonprofit Innovation.

Through the Creating Hope Act, Kids v Cancer has mobilized almost $1 billion for research and development of drugs. With the valuation of a Creating Hope Act pediatric priority review voucher reaching $350 million, biotech and pharmaceutical companies are now focusing on business plans built around pediatric rare disease drug development.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
By Rodney Haring
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account